Les, I.; MartÃnez, M.; Pérez-Francisco, I.; Cabero, M.; Teijeira, L.; Arrazubi, V.; Torrego, N.; Campillo-Calatayud, A.; Elejalde, I.; Kochan, G.;
et al. Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events. Cancers 2023, 15, 1629.
https://doi.org/10.3390/cancers15051629
AMA Style
Les I, MartÃnez M, Pérez-Francisco I, Cabero M, Teijeira L, Arrazubi V, Torrego N, Campillo-Calatayud A, Elejalde I, Kochan G,
et al. Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events. Cancers. 2023; 15(5):1629.
https://doi.org/10.3390/cancers15051629
Chicago/Turabian Style
Les, Iñigo, Mireia MartÃnez, Inés Pérez-Francisco, MarÃa Cabero, LucÃa Teijeira, Virginia Arrazubi, Nuria Torrego, Ana Campillo-Calatayud, Iñaki Elejalde, Grazyna Kochan,
and et al. 2023. "Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events" Cancers 15, no. 5: 1629.
https://doi.org/10.3390/cancers15051629
APA Style
Les, I., MartÃnez, M., Pérez-Francisco, I., Cabero, M., Teijeira, L., Arrazubi, V., Torrego, N., Campillo-Calatayud, A., Elejalde, I., Kochan, G., & Escors, D.
(2023). Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events. Cancers, 15(5), 1629.
https://doi.org/10.3390/cancers15051629